Home HLA and Immune Genetics HLA Typing Test: Immune Matching, Transplant, Disease Risk, and Results

HLA Typing Test: Immune Matching, Transplant, Disease Risk, and Results

By
Vita Library
-
2
Understand HLA typing methods, allele names, resolution, transplant matching, disease associations, drug-reaction risk, specimen issues, and result interpretation.

An HLA typing test identifies a person’s inherited human leukocyte antigen variants. HLA proteins guide immune recognition, so typing is used to match transplant donors and recipients, investigate certain disease associations, and support medication-safety testing. The same phrase can describe very different tests: a transplant workup may type many HLA genes at high resolution, while a disease-risk test may look only for HLA-B27 or HLA-DQ2/DQ8. Results are usually written as allele names such as HLA-A02:01 or HLA-B27:05. They are not positive or negative unless the laboratory is answering a specific question. HLA type remains stable throughout life, but the correct specimen matters after an allogeneic stem-cell transplant because blood cells may carry the donor’s HLA. Typing does not measure HLA antibodies, immune strength, or active rejection. Accurate interpretation requires the test purpose, loci examined, resolution, and clinical context. A result useful for one application may be insufficient for another.

  • HLA typing identifies inherited HLA alleles; it does not measure antibodies or inflammation.
  • Transplant testing often requires high-resolution typing across several class I and class II genes.
  • Disease-associated HLA alleles raise or lower probability but rarely diagnose disease alone.
  • Drug-risk HLA tests must identify the exact allele named in the prescribing recommendation.
  • After donor stem-cell transplant, blood may show donor HLA and another tissue may be needed for the recipient’s original type.

Table of Contents

What HLA Typing Measures

Human leukocyte antigens are cell-surface proteins encoded by a dense group of genes on chromosome 6. They bind short protein fragments and display them to T cells. This system allows the immune response to distinguish normal self, infection, altered cells, and transplanted tissue.

The classical HLA genes are divided into two groups:

  • Class I: HLA-A, HLA-B, and HLA-C, expressed on nearly all nucleated cells
  • Class II: HLA-DR, HLA-DQ, and HLA-DP molecules, expressed mainly on antigen-presenting immune cells and induced on other cells during inflammation

Class II molecules are assembled from alpha and beta chains. Important genes include HLA-DRA and HLA-DRB1, HLA-DQA1 and HLA-DQB1, and HLA-DPA1 and HLA-DPB1. Some people also carry additional DRB genes such as DRB3, DRB4, or DRB5.

HLA genes are highly polymorphic, meaning thousands of allele versions exist. This diversity helps populations present a broad range of microbial peptides, but it makes donor-recipient matching difficult.

A person inherits one HLA haplotype from each biological parent. The haplotype contains linked alleles across the HLA region. Because the genes are close together, they are often inherited as a block. Two biological siblings have about a 25% chance of inheriting the same two parental haplotypes.

Typing identifies the alleles or antigen groups in the tested DNA. It does not directly show:

  • Whether HLA antibodies are present
  • Whether a transplant crossmatch is positive
  • Whether rejection or graft-versus-host disease is occurring
  • Whether the immune system is weak or overactive
  • Whether a disease-associated allele is causing symptoms

For antibody questions, a separate HLA antibody test is required. For donor compatibility, both donor and recipient types are compared and antibody findings are added.

Why HLA Typing Is Ordered

HLA typing is ordered for several distinct clinical purposes. The laboratory needs to know the purpose because it determines which genes, alleles, and resolution are necessary.

Solid-organ transplantation

Kidney, pancreas, heart, lung, liver, and other transplant programs type recipients and donors. HLA data supports matching, virtual crossmatch, unacceptable-antigen avoidance, and long-term immune-risk assessment. Kidney programs have traditionally emphasized HLA-A, HLA-B, and HLA-DR, but HLA-C, DQ, and DP are increasingly relevant to antibody analysis.

Bone marrow and stem-cell transplantation

Allogeneic hematopoietic cell transplant requires detailed donor selection. High-resolution typing commonly includes HLA-A, B, C, DRB1, and DQB1, with DPB1 and additional loci evaluated according to the protocol. The registry uses typing to identify matched unrelated donors and cord-blood units.

Disease association

Certain HLA alleles are associated with disease. Examples include HLA-B27 with axial spondyloarthritis, HLA-DQ2/DQ8 with celiac disease, and particular HLA-DRB1 alleles with rheumatoid arthritis. These tests modify probability; they usually do not diagnose the condition alone.

Medication hypersensitivity

Some HLA alleles predict severe immune-mediated drug reactions. Clinically important examples include HLA-B57:01 before abacavir, HLA-B15:02 and HLA-A31:01 for carbamazepine in relevant populations, and HLA-B58:01 for allopurinol. A targeted pharmacogenetic test must distinguish the exact allele specified by the guideline.

Platelet and transfusion support

HLA typing can help select HLA-compatible platelets for patients who are refractory because of anti-HLA antibodies. Donor registries may type volunteer platelet donors at selected loci.

Forensic, family, and research uses

HLA was historically used in parentage testing, but modern short tandem repeat testing is more accurate. HLA typing remains important in population genetics, immunology research, vaccine studies, and investigation of disease mechanisms.

The intended use should appear on the requisition. A low-resolution disease marker result may not be adequate for transplant donor selection, and a transplant report may not automatically include a validated pharmacogenetic interpretation.

Testing Methods and Resolution

HLA typing has moved from antibody-based serology to DNA sequencing. Laboratories may still use more than one method, especially for confirmation or urgent deceased-donor testing.

Serologic typing

Serology uses panels of antibodies to identify broad HLA antigens on lymphocytes. Results look like HLA-A2 or HLA-B44. The method is fast but has limited resolution and can be difficult after transfusion, immunosuppression, or low cell viability. It cannot distinguish many allele-level differences.

Sequence-specific oligonucleotide testing

SSO testing amplifies HLA DNA and uses probes that bind selected sequence motifs. The pattern narrows the possible alleles. It is efficient for medium-throughput work but can leave ambiguity when several alleles share the tested motifs.

Sequence-specific primer testing

SSP uses primer pairs designed to amplify only certain HLA variants. The presence or absence of amplification identifies allele groups. It can be rapid and useful for targeted or confirmatory typing but requires many reactions for broad high-resolution analysis.

Sanger sequence-based typing

Sanger sequencing reads HLA exons, often those encoding the peptide-binding region. Because both inherited copies are read together, phase ambiguity can occur: the laboratory may know the sequence variants present but not which changes belong on the same allele.

Next-generation sequencing

NGS reads many DNA molecules in parallel and can cover multiple exons, introns, and untranslated regions. Longer phased reads reduce ambiguity and support high-resolution allele assignment. NGS is now common for stem-cell donor registries and confirmatory transplant typing.

Long-read sequencing

Long-read platforms can sequence an entire HLA gene on one molecule, improving phase and revealing rare or novel alleles. Cost, validation, error profiles, and workflow still affect routine adoption.

Resolution describes how specifically the result identifies an allele:

  • Low resolution: broad antigen or first-field allele group, such as HLA-A*02
  • High resolution: specific protein sequence, commonly two fields, such as HLA-A*02:01
  • Allelic resolution: resolves differences outside the coding sequence when required, such as HLA-A*02:01:01:01

The phrase “four-digit typing” is still used for two-field results, but colon-separated nomenclature is more accurate because the number of digits varies.

Urgent deceased-donor typing may begin with a rapid method and later receive confirmatory higher-resolution testing. The transplant team should know whether a result is preliminary or final.

How to Read HLA Allele Names

An HLA allele name contains several parts. Consider HLA-B*57:01:01:01N as a general naming example, though the exact suffix and fields vary.

  • HLA-B identifies the gene.
  • The asterisk separates the gene from the allele designation.
  • The first field, 57, identifies an allele group often related to a serologic antigen.
  • The second field, 01, identifies a specific protein sequence.
  • The third field distinguishes synonymous coding changes that do not alter the protein.
  • The fourth field identifies differences in noncoding regions.
  • A suffix can describe expression; N means a null allele that is not normally expressed.

Other suffixes include L for low expression, S for secreted, C for cytoplasmic, A for aberrant expression, and Q for questionable expression. Expression variants can be clinically important because a sequence that looks matched may not produce the expected surface protein.

A person normally has two allele results at each autosomal HLA locus, one from each parent. If both are the same, the person is homozygous at that locus. If different, the person is heterozygous.

A typing report may show ambiguity, such as several possible allele combinations. This does not necessarily mean the test failed. The tested sequence may be identical among those alleles in the regions examined. Additional exons, family typing, or a different sequencing method can resolve the ambiguity when clinically necessary.

Novel alleles may not yet have an official World Health Organization HLA name. The laboratory may report a provisional sequence and submit it for naming. A new allele is not automatically harmful; most HLA variation is normal population diversity.

Older reports may use serologic names such as A2, B27, or DR4. These broad groups can contain many molecular alleles. For example, several HLA-B*27 alleles share the B27 antigen but do not have identical disease associations.

Do not remove punctuation from allele names. HLA-A31:01 and HLA-B15:02 are distinct, precise results. A broad “HLA-A31 positive” report may be insufficient for a medication decision unless the method specifically confirms the required allele.

HLA Typing for Transplant Matching

Transplant interpretation compares donor and recipient types. A match score only makes sense when the counted loci and resolution are specified.

In kidney transplantation, a report may count antigen mismatches at HLA-A, B, and DR, giving zero to six mismatches. A “zero mismatch” kidney may still differ at HLA-C, DQ, DP, allele, or epitope level. Modern programs use additional typing to interpret donor-specific antibodies and molecular mismatch.

In unrelated stem-cell transplantation, 8/8 commonly means allele-level matching at HLA-A, B, C, and DRB1. A 10/10 match adds DQB1. DPB1 is often considered separately because many otherwise matched pairs differ there; some DPB1 mismatches are classified as permissive and others as nonpermissive.

A haploidentical donor shares one inherited HLA haplotype with the recipient. Biological parents and children are typically haploidentical, and about half of siblings are. Modern post-transplant cyclophosphamide and other strategies have made haploidentical transplantation widely feasible.

Typing alone does not establish compatibility. The laboratory must compare recipient antibody specificity with donor HLA. A donor can have a favorable match count yet carry one HLA target against which the recipient has a strong antibody. The resulting donor-specific antibody may produce a positive crossmatch result and high rejection or graft-failure risk.

Conversely, a partially matched donor with no targeted HLA and a negative crossmatch may be acceptable. Transplant decisions also incorporate donor age and health, organ function, cell source, infection status, urgency, size, blood group, and treatment platform.

Molecular matching examines amino-acid or eplet differences between donor and recipient HLA. These measures may estimate the chance of forming antibodies more precisely than a simple allele count. They remain supplementary, and software methods or clinical thresholds are not fully standardized.

Confirmatory typing is important before an irreversible step such as donor mobilization or transplant surgery. Independent samples reduce the risk of labeling or identity error.

Disease Associations and Drug-Reaction Risk

HLA alleles can influence which peptides are presented to immune cells. This creates strong associations with some inflammatory diseases and drug reactions, but association is not the same as causation.

HLA-B27 is found in most people with ankylosing spondylitis in many European-ancestry populations, yet most people who carry HLA-B27 never develop the disease. A positive result supports evaluation when inflammatory back pain or uveitis is present; it is not a screening diagnosis for an asymptomatic person.

HLA-DQ2.5, DQ2.2, or DQ8 is present in nearly all people with celiac disease, making absence useful for ruling disease out in many situations. Presence is common in healthy people, so a positive result cannot replace celiac antibody tests and biopsy when indicated.

HLA-DRB1 “shared epitope” alleles increase rheumatoid arthritis susceptibility and can influence disease phenotype, but clinical diagnosis still depends on joint findings, serology, and imaging.

Drug-associated HLA tests can be more actionable because avoiding one medication can prevent a rare but severe reaction. Examples include:

  • HLA-B*57:01 and abacavir hypersensitivity
  • HLA-B*15:02 and carbamazepine-associated Stevens-Johnson syndrome or toxic epidermal necrolysis in high-prevalence ancestry groups
  • HLA-A*31:01 and a broader range of carbamazepine hypersensitivity reactions
  • HLA-B*58:01 and allopurinol severe cutaneous adverse reactions

A negative result lowers allele-related risk but does not guarantee safety. Patients can develop non-HLA adverse effects, and positive status does not mean a reaction has already occurred.

The test must be validated for the exact allele. Broad serology, imputation, or raw consumer genotype data may not reliably distinguish closely related alleles. Medication should not be stopped or started solely from an unconfirmed result.

HLA disease-risk testing is most useful when it answers a focused clinical question. Broad HLA sequencing in a healthy person can generate associations that are weak, ancestry-dependent, or not medically actionable.

Limitations and Unexpected Results

HLA typing is technically demanding because the genes are highly similar, polymorphic, and sometimes duplicated. Limitations depend on method and specimen.

A low-resolution test can group several alleles together. An ambiguous result may not distinguish which variants are on the same chromosome. Targeted assays can miss rare alleles if primers or probes do not bind as expected. NGS may have coverage gaps or difficulty with novel structural variants.

Allele databases expand continually. A result assigned years ago may be refined after new alleles are recognized or nomenclature changes. The DNA itself did not change; the reference system improved.

The specimen can produce unexpected results:

  • After allogeneic stem-cell transplant, blood DNA may largely represent the donor.
  • Recent transfusion rarely changes DNA typing substantially when leukoreduced products are used, but mixed-cell signals can occur in special settings.
  • A transplanted organ does not usually change blood HLA typing, though donor-derived cell-free DNA is detectable by specialized assays.
  • Cancer, especially blood cancer, can cause loss of an HLA allele in tumor cells without changing the inherited germline type.
  • Cheek swabs can contain blood leukocytes, which matters after stem-cell transplant.

For the recipient’s original HLA after stem-cell transplant, laboratories may use pretransplant samples, cultured skin fibroblasts, hair follicles, or another validated nonhematopoietic source.

HLA typing can reveal unexpected biological relationships. A sibling thought to be HLA-identical may not share the expected haplotypes; sample error must be excluded before drawing conclusions. Programs should counsel families that genetic testing can incidentally raise questions about parentage or relatedness.

Typing does not measure expression perfectly. Null or low-expression alleles may require special interpretation. Some assays report the sequence but not whether the protein is displayed normally.

Disease associations differ among ancestries and allele subtypes. A broad B27 antigen may include variants with different population frequencies. Risk estimates from one population may not transfer directly to another.

Next Steps After HLA Typing

Start by identifying why the test was ordered. Then ask whether the loci, resolution, and specimen were appropriate for that purpose.

For a transplant result, ask:

  1. Which genes were typed in donor and recipient?
  2. Is the result preliminary or confirmatory?
  3. What resolution was achieved?
  4. Are any allele ambiguities clinically relevant?
  5. What is the match score and which loci are mismatched?
  6. Does the recipient have donor-specific antibodies?
  7. What do the virtual and physical crossmatches show?
  8. Are DPB1 permissiveness, eplets, or expression factors being used?

For a disease-association test, interpret the result with symptoms and baseline prevalence. A positive HLA-B27 does not explain mechanical back pain by itself. A negative result may lower disease probability without eliminating it. Follow-up should focus on the clinical syndrome rather than the gene alone.

For a medication test, confirm the exact allele and the guideline that applies. The prescribing clinician or pharmacist should document the result in the medication record so testing does not need to be repeated. HLA genotype does not usually change, although a questionable or low-resolution result may need confirmation.

Keep the full laboratory report, including method, allele names, resolution, and date. A simplified patient-portal label can omit important details. Share the report when moving between transplant centers or specialists.

If the result is unexpected after a stem-cell transplant, tell the laboratory the transplant date and donor type. Do not interpret donor-derived blood HLA as the recipient’s inherited disease or drug-risk genotype without specialist review.

Family testing should be targeted to a clear purpose. For transplant donation, each potential donor receives independent typing. For disease risk, testing healthy relatives may provide little benefit unless a clinician has identified an actionable question.

HLA typing is a durable genetic record, but its clinical meaning depends on context. The same allele can be valuable for donor matching, irrelevant to current symptoms, or crucial before one specific medication. Accurate use begins with the exact question the test was designed to answer.

Resolution should be chosen before the sample is tested. Broad antigen-level typing can answer an urgent allocation question, while unrelated stem-cell donor selection, allele-restricted therapy, or pharmacogenetics may require protein-level or higher resolution. Ordering the most detailed test is not always necessary, but ordering too little can delay care when a second sample or confirmatory assay is needed.

Clinical laboratories also use quality controls that are not visible in the final allele list. They check read depth, phase, allele balance, contamination, and consistency across linked loci. Novel or rare sequences may be reported provisionally and confirmed by another method. When a result will determine donor collection, transplant acceptance, or an irreversible drug decision, confirmatory typing from an independently collected specimen is common practice.

A result should be stored as the full allele list, not only as a match fraction or a statement such as “HLA compatible.” Future laboratories may need the original resolution, phase, expression suffixes, and specimen date to compare a new donor, interpret an antibody, or confirm eligibility for an allele-restricted therapy. The inherited genotype is stable, but the clinical question and required precision can change.

References

Disclaimer

This article provides general information and cannot interpret an individual HLA type for transplant, disease, or medication use. Results should be reviewed by the ordering clinician and, for transplantation, a qualified histocompatibility laboratory. Do not make donor or medication decisions from an incomplete, consumer, or low-resolution result.

RELATED ARTICLESMORE FROM AUTHOR